South Korea Bronchodilators Market Size, Share, and COVID-19 Impact Analysis, By Disease (Asthma and COPD), By Route of Administration (Inhalable and Oral), By Drug Class (Beta-Adrenergic and Anticholinergics), and South Korea Bronchodilators Market Insights, Industry Trend, Forecasts to 2035

South Korea Bronchodilators Market Insights Forecasts to 2035

• The South Korea Bronchodilators Market Size Was Estimated at USD 670.7 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.60% from 2025 to 2035
• The South Korea Bronchodilators Market Size is Expected to Reach USD 1221.0 Million by 2035

According to a research report published by Spherical Insights and Consulting, The South Korea Bronchodilators Market Size is anticipated to reach USD 1221.0 Million by 2035, growing at a CAGR of 5.60%from 2025 to 2035. The market for bronchodilators is expanding as a result of several causes, including the aging population, the rise in lung disorders, and increased understanding of how to treat lung diseases, all of which are being facilitated by increased research and development activities by major market participants.

Market Overview

The bronchodilator market involves the production and sale of medications that relax bronchial muscles, improving airflow to the lungs and treating respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. These drugs provide quick relief from symptoms such as wheezing, shortness of breath, and chest tightness. The rising prevalence of respiratory diseases, urban pollution, and smoking habits. Opportunities include increased demand for combination therapies, advancements in inhalation drug delivery systems, and expanding healthcare access in developing nations. Governments are launching initiatives such as anti-smoking campaigns, asthma awareness programs, and subsidies for essential respiratory medications, encouraging early diagnosis and treatment. These efforts collectively support innovation, accessibility, and expansion in the bronchodilator market.

Report Coverage

This research report categorizes the market for South Korea bronchodilators market based on various segments and regions forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea bronchodilators market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea bronchodilators market.

Driving Factors

The bronchodilator market is driven by the increasing prevalence of respiratory diseases such as asthma and COPD, largely due to rising air pollution, smoking, and aging populations. Growing awareness of respiratory health and improved healthcare infrastructure, especially in developing regions, further rising demand. Technological advancements in drug delivery systems, such as metered-dose inhalers and nebulizers, enhance treatment effectiveness and patient compliance. Additionally, government initiatives and reimbursement policies promoting early diagnosis and access to essential respiratory medications support market expansion.

Restraining Factors

High treatment costs, particularly for long-term therapies and combination inhalers, can limit accessibility, especially in low-income regions with inadequate healthcare coverage. Stringent regulatory requirements, including extensive clinical trials and lengthy approval processes, can delay the introduction of new treatments and increase development costs. Additionally, potential side effects such as tremors, increased heart rate, and palpitations may deter patient adherence to prescribed therapies. Furthermore, the emergence of generics and biosimilars intensifies market competition, potentially impacting the profitability of branded bronchodilator products.

Market Segmentation

The South Korea Bronchodilators Market share is classified into disease, route of administration, and drug class.

• The asthma segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea bronchodilators market is segmented by grade into asthma and COPD. Among these, the asthma segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segment's dominance is explained by the rising incidence of asthma in the general population. With a large number of candidates in late or mid-stage development, the area boasts a robust research pipeline. To improve drug adherence, double and triple combination inhalers for asthma are also nearing completion.

• The inhalable segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea bronchodilators market is segmented by route of administration into inhalable and oral. Among these, the inhalable segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The most popular way to administer bronchodilators is by nasal or inhalation. This method of administration is frequently employed as a nebulizer, dry powder inhaler, soft mist inhaler, and metered-dose inhaler (MDI).

• The beta-adrenergic segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea bronchodilators market is segmented by drug class into beta-adrenergic and anticholinergics. Among these, the beta-adrenergic segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. To dilate bronchial airways, beta-adrenergic bronchodilators relax the muscles around the airways. These drugs, which are beta-2 agonists, dilate airways by targeting receptors on smooth muscle cells.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea bronchodilators market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Hanmi Pharmaceutical
• Chong Kun Dang Pharmaceutical
• Daewoong Pharmaceutical
• Yuhan Corporation
• Samsung Biologics
• GC Pharma
• Boditech Med
• KTMED Inc.
• Teleflex Incorporated
• Fisher & Paykel Healthcare
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea bronchodilators market based on the below-mentioned segments:

South Korea Bronchodilators Market, By Disease

• Asthama
• COPD

South Korea Bronchodilators Market, By Route of Administration

• Inhalable
• Oral

South Korea Bronchodilators Market, By Drug Class

• Beta-Adrenergic
• Anticholinergics